SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-008984
Filing Date
2022-05-10
Accepted
2022-05-10 16:17:06
Documents
62
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q janx-20220331.htm   iXBRL 10-Q 2428382
2 EX-31.1 janx-ex31_1.htm EX-31.1 20237
3 EX-31.2 janx-ex31_2.htm EX-31.2 19065
4 EX-32.1 janx-ex32_1.htm EX-32.1 18046
  Complete submission text file 0000950170-22-008984.txt   9436445

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT janx-20220331.xsd EX-101.SCH 48755
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT janx-20220331_cal.xml EX-101.CAL 45212
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT janx-20220331_pre.xml EX-101.PRE 300604
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT janx-20220331_def.xml EX-101.DEF 182738
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT janx-20220331_lab.xml EX-101.LAB 415133
56 EXTRACTED XBRL INSTANCE DOCUMENT janx-20220331_htm.xml XML 2136816
Mailing Address 11099 TORREY PINES PARK ROAD SAN DIEGO CA 92037
Business Address 11099 TORREY PINES PARK ROAD SAN DIEGO CA 92037 858-750-4700
Janux Therapeutics, Inc. (Filer) CIK: 0001817713 (see all company filings)

IRS No.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40475 | Film No.: 22909868
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences